US retinal specialists identify 4D Molecular Therapeutics’ 4D-150, Adverum Biotechnologies’ Ixo-vec, and Johnson & Johnson’s JNJ-1887 as most likely pipeline
Spherix Global Insights recently delved into the efficacy, patient quality of life, and symptom management of adalimumab vs secukinumab. Managing
Takeda’s resurrection of the once-rejected Eohilia appears to be paying off, with a survey of physicians finding the launch is in line
Impacts of Eohilia’s short-term 12-week label are still unfolding, but prescribers express interest in continuing consecutive treatment courses. EXTON, PA.,
Epileptologists and general neurologists have different approaches to treating people with refractory epilepsy, according to the Market Dynamix: Adult Refractory
New brands aiming to enter the refractory epilepsy market may face challenges achieving desired penetration without improved general neurologist education
Ophthalmologists are cautious about prescribing the current geographic atrophy (GA) treatment options Syfovre and Izervay, introduced in 2023 as the
Spherix Global Insights releases market landscape evolution study paired with new research tracking familiarity and uptake of Novartis’ Fabhalta and
New prescriptions for Vabysmo and Eylea HD outpace reported current brand share, indicating further growth of the brands, according to
Leigh Anne Siino joins executive team to accelerate company’s revenue growth. EXTON, PA., June 17, 2024 — Spherix Global Insights, a
Pending regulatory submission, Fabhalta (iptacopan) could become the first approved therapy for C3G, addressing a significant unmet need in nephrology,
As treatment strategies evolve, rheumatologists are refining SLE care with targeted biologics, driving a paradigm shift in lupus management, according
